Contact Us
Drug Search Results
More Filters [+]

Ribavirin

Alternative Names: ribavirin, virazole, copegus, rebetol, ribavirine, vilona, ribasphere, ribavarin, sch 18908, virazole (ribavirin) inhalation solution
Latest Update: 2024-10-22
Latest Update Note: News Article

Product Description

Ribavirin, a broad spectrum, non-interferon-inducing virustatic chemotherapeutic agent, demonstrates activity against a wide range of RNA and DNA viruses, including the retrovirus known to cause the acquired immune deficiency syndrome.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/3021519/)

Mechanisms of Action: IMPDH Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Japan | Jordan | Korea | Latvia | Lithuania | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Liver Cirrhosis | Hepatitis | Hepatitis, Chronic | Hepatitis C | Hepatitis C, Chronic | Hepatitis | Hepatitis, Chronic | Hepatitis C | Hepatitis C, Chronic | HIV Infections

Known Adverse Events: Headache | Erythema | Anemia | Anemia, Hemolytic | Neutropenia | Myalgia | Anorexia | Asthenia

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ribavirin

Countries in Clinic: Taiwan

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Hepatitis C, Chronic

Phase 1: Hepatitis A

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2015-000111-41

P3

Completed

Hepatitis C, Chronic

2023-05-01

A20-102

P1

Completed

Hepatitis A|Hepatitis C, Chronic

2022-07-18

21%

Recent News Events

Date

Type

Title

10/22/2024

News Article

 NanoViricides President Dr. Diwan to Present at the PODD Conference

10/22/2024

News Article

 Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024

09/04/2024

News Article

 Hepatitis Therapeutics Market Size worth USD 21.9 Billion by 2031, with a CAGR of 3.6% - Transparency Market Research, Inc.

08/08/2024

News Article

 NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions